Allspring Global Investments Holdings LLC Purchases 119,906 Shares of Natera, Inc. (NASDAQ:NTRA)

Allspring Global Investments Holdings LLC grew its position in shares of Natera, Inc. (NASDAQ:NTRA) by 13.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 983,312 shares of the medical research company’s stock after buying an additional 119,906 shares during the period. Allspring Global Investments Holdings LLC owned approximately 0.80% of Natera worth $106,483,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. grew its stake in shares of Natera by 0.7% in the first quarter. Vanguard Group Inc. now owns 11,044,743 shares of the medical research company’s stock valued at $1,010,152,000 after acquiring an additional 72,848 shares in the last quarter. Farallon Capital Management LLC grew its position in shares of Natera by 13.0% during the 1st quarter. Farallon Capital Management LLC now owns 3,927,683 shares of the medical research company’s stock worth $359,226,000 after purchasing an additional 452,800 shares in the last quarter. Principal Financial Group Inc. increased its holdings in shares of Natera by 7.1% during the fourth quarter. Principal Financial Group Inc. now owns 1,703,615 shares of the medical research company’s stock worth $106,714,000 after purchasing an additional 112,825 shares during the period. Norges Bank acquired a new stake in shares of Natera in the fourth quarter valued at approximately $83,970,000. Finally, Avidity Partners Management LP raised its position in shares of Natera by 23.5% in the fourth quarter. Avidity Partners Management LP now owns 1,110,000 shares of the medical research company’s stock valued at $69,530,000 after buying an additional 211,000 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Activity

In related news, insider Jonathan Sheena sold 12,000 shares of the business’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $121.01, for a total value of $1,452,120.00. Following the sale, the insider now owns 287,441 shares of the company’s stock, valued at $34,783,235.41. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Natera news, insider Daniel Rabinowitz sold 1,057 shares of the stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $102.77, for a total transaction of $108,627.89. Following the completion of the sale, the insider now owns 206,400 shares of the company’s stock, valued at approximately $21,211,728. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jonathan Sheena sold 12,000 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $121.01, for a total transaction of $1,452,120.00. Following the completion of the transaction, the insider now owns 287,441 shares in the company, valued at approximately $34,783,235.41. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 94,388 shares of company stock valued at $10,425,404. Insiders own 7.60% of the company’s stock.

Natera Price Performance

Shares of NTRA opened at $118.11 on Tuesday. The company has a quick ratio of 3.98, a current ratio of 4.12 and a debt-to-equity ratio of 0.36. The stock has a market cap of $14.50 billion, a PE ratio of -37.86 and a beta of 1.48. Natera, Inc. has a 12-month low of $36.90 and a 12-month high of $124.83. The business has a 50-day simple moving average of $110.17 and a two-hundred day simple moving average of $99.49.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.39. Natera had a negative return on equity of 49.72% and a negative net margin of 30.24%. The company had revenue of $413.35 million during the quarter, compared to the consensus estimate of $343.00 million. During the same quarter in the prior year, the firm posted ($0.97) earnings per share. The firm’s revenue was up 58.1% compared to the same quarter last year. Analysts anticipate that Natera, Inc. will post -2.43 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. Stephens restated an “overweight” rating and set a $125.00 price objective on shares of Natera in a research note on Friday, August 9th. StockNews.com upgraded shares of Natera from a “sell” rating to a “hold” rating in a research report on Tuesday, August 20th. Morgan Stanley upped their price target on shares of Natera from $125.00 to $132.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. UBS Group decreased their price objective on shares of Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. Finally, Robert W. Baird upped their target price on Natera from $117.00 to $120.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. One investment analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and an average target price of $119.07.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.